priliximab
mAbexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- T-cell surface antigen CD4INHIBITOR
CD4 inhibitor
- T-cell surface antigen CD4NEGATIVE MODULATOR
CD4 negative modulator
Blocks activation of T-cells. Causes depletion of CD4+ lymphocytes.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109473 ↗
- ChEMBLCHEMBL2108475 ↗
Also known as
- cen-000029
- centara
- cm-mt412
- mt-412
- priliximab